Cargando…

Triple therapy with low‐dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes

AIM: To evaluate the efficacy and safety of triple therapy with low‐dose dapagliflozin plus saxagliptin added to metformin in uncontrolled type 2 diabetes. MATERIALS AND METHODS: This 24‐week, double‐blind trial (NCT02681094) randomized 883 patients (glycated haemoglobin [HbA1c] 7.5‐10.0%) on metfor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosenstock, Julio, Perl, Shira, Johnsson, Eva, García‐Sánchez, Ricardo, Jacob, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771748/ https://www.ncbi.nlm.nih.gov/pubmed/31144431 http://dx.doi.org/10.1111/dom.13795

Ejemplares similares

Sustained 52‐week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes
por: Handelsman, Yehuda, et al.
Publicado: (2019)

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin
por: Del Prato, Stefano, et al.
Publicado: (2018)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
por: Rosenstock, Julio, et al.
Publicado: (2018)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Dapagliflozin plus saxagliptin add‐on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes
por: Johansson, Lars, et al.
Publicado: (2020)

Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis
por: Zhuang, Yan, et al.
Publicado: (2020)

The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes
por: Mathieu, Chantal, et al.
Publicado: (2018)

Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
por: Yu, Huan, et al.
Publicado: (2017)

Efficacy and safety of dual add‐on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52‐week, randomized, active‐controlled trial
por: Frias, Juan P., et al.
Publicado: (2020)

Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, Phase 3 trial
por: Vilsbøll, Tina, et al.
Publicado: (2020)

Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures
por: Neutel, Joel M., et al.
Publicado: (2013)

Cost-Effectiveness of Saxagliptin Compared With Glibenclamide as a Second-Line Therapy Added to Metformin for Type 2 Diabetes Mellitus in Ethiopia
por: Bekele, Mengistu, et al.
Publicado: (2021)

Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment
por: Perl, Shira, et al.
Publicado: (2016)

Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study
por: Stack, Austin G, et al.
Publicado: (2020)

A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy
por: White, Judith L, et al.
Publicado: (2014)

Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice
por: Alshamrani, Ali A., et al.
Publicado: (2023)

Bioequivalence of saxagliptin/dapagliflozin fixed‐dose combination tablets compared with coadministration of the individual tablets to healthy subjects
por: Vakkalagadda, Blisse, et al.
Publicado: (2016)

Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial
por: Koshino, Akihiko, et al.
Publicado: (2023)

Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults
por: Minze, Molly G., et al.
Publicado: (2013)

Effectiveness of triple therapy with dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity, Cali-Colombia
por: Joaqui, Vanessa Bedoya, et al.
Publicado: (2021)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial
por: Frías, Juan P., et al.
Publicado: (2018)

Life-Threatening Acidosis With Metformin and Dapagliflozin Combination Therapy: A Case Report
por: Gupta, Sushan, et al.
Publicado: (2023)

Impact of Dapagliflozin Therapy on Renal Protection and Kidney Morphology in Patients With Uncontrolled Type 2 Diabetes Mellitus
por: Sugiyama, Seigo, et al.
Publicado: (2018)

Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination
por: Panagoulias, George S, et al.
Publicado: (2014)

Clinical outcomes, not clinical utility, should be the major consideration for saxagliptin with or without metformin
por: Doggrell, Sheila A
Publicado: (2014)

Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China
por: Hou, Xingyun, et al.
Publicado: (2019)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION‐8 study
por: Jabbour, Serge A., et al.
Publicado: (2018)

Editing the Shape Morphing of Monocomponent Natural Polysaccharide Hydrogel Films
por: Hu, Hao, et al.
Publicado: (2021)

Efficacy and Safety of Saxagliptin as Add-On Therapy in Type 2 Diabetes
por: Neumiller, Joshua J.
Publicado: (2014)

Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes
por: Sosale, Bhavana, et al.
Publicado: (2016)

Long‐term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104‐week extension to a 52‐week randomized, phase 3 study and liver fat MRI substudy
por: Frías, Juan P., et al.
Publicado: (2021)

Open and Closed Triple Inhaler Therapy in Patients with Uncontrolled Asthma
por: Kotoulas, Serafeim-Chrysovalantis, et al.
Publicado: (2023)

Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes
por: Sharma, Morali D
Publicado: (2010)

Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II
por: Torre, Enrico, et al.
Publicado: (2020)

Kombiglyze (metformin and saxagliptin)‐induced hepatotoxicity in a patient with non‐alcoholic fatty liver disease
por: Thalha, Abdul Malik, et al.
Publicado: (2018)

Monocomponent chemoembolization in oral and oropharyngeal cancer using an aqueous crystal suspension of cisplatin
por: Kovács, A F, et al.
Publicado: (2002)

Recent Advances in Monocomponent Visible Light Photoinitiating Systems Based on Sulfonium Salts
por: Dumur, Frédéric
Publicado: (2023)

Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION‐7 randomized study
por: Guja, Cristian, et al.
Publicado: (2018)

Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials
por: Sjöstrand, Mikaela, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_er9c0t5ijtjcl87od4n0om7go1